{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T18:49:24Z","timestamp":1771267764546,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.ejca.2018.04.004","type":"journal-article","created":{"date-parts":[[2018,5,4]],"date-time":"2018-05-04T19:03:01Z","timestamp":1525460581000},"page":"7-15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["Efficacy and safety of single-agent pan-human epidermal growth factor receptor (HER) inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer"],"prefix":"10.1016","volume":"97","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1294-6859","authenticated-orcid":false,"given":"S.","family":"Cavalieri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Perrone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Miceli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.A.","family":"Ascierto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.D.","family":"Locati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Bergamini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Granata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Alfieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Resteghini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Galbiati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Busico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Paielli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Patuzzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Maurichi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Gallino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Ruggeri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Mariani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Palla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Licitra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Bossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.ejca.2018.04.004_bib1","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/j.ejca.2015.06.110","article-title":"Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline","volume":"51","author":"Stratigos","year":"2015","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1016\/j.ejca.2018.04.004_bib2","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/S1470-2045(08)70178-5","article-title":"Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study","volume":"9","author":"Brantsch","year":"2008","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2018.04.004_bib3","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1200\/JCO.1990.8.2.342","article-title":"Cisplatin-based chemotherapy in advanced basal and squamous cell carcinomas of the skin: results in 28 patients including 13 patients receiving multimodality therapy","volume":"8","author":"Guthrie","year":"1990","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2018.04.004_bib4","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1365-2133.2006.07603.x","article-title":"Characterization of the expression and activation of the epidermal growth factor receptor in squamous cell carcinoma of the skin","volume":"156","author":"Fogarty","year":"2007","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.ejca.2018.04.004_bib5","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0959-8049(00)00364-6","article-title":"Coexpression patterns of EGFR, HER2, HER3 and HER4 in non-melanoma skin cancer","volume":"37","author":"Kr\u00e4hn","year":"2001","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2018.04.004_bib6","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.humpath.2007.07.004","article-title":"Epidermal growth factor receptor: a novel biomarker for aggressive head and neck cutaneous squamous cell carcinoma","volume":"39","author":"Ch'ng","year":"2008","journal-title":"Hum Pathol"},{"issue":"25","key":"10.1016\/j.ejca.2018.04.004_bib7","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1200\/JCO.2010.34.1735","article-title":"Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin","volume":"29","author":"Maubec","year":"2011","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2018.04.004_bib8","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1158\/1078-0432.CCR-11-1951","article-title":"A phase II study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck","volume":"18","author":"Lewis","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.ejca.2018.04.004_bib9","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1097\/CAD.0b013e32809ef9e0","article-title":"Cutaneous squamous cell carcinoma responding serially to single-agent cetuximab","volume":"18","author":"Suen","year":"2007","journal-title":"Anticancer Drugs"},{"issue":"1","key":"10.1016\/j.ejca.2018.04.004_bib10","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1365-2133.2005.06709.x","article-title":"Treatment with gefitinib (ZD 1839) in a patient with advanced cutaneous squamous cell carcinoma","volume":"153","author":"Baltaci","year":"2005","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.ejca.2018.04.004_bib11","doi-asserted-by":"crossref","first-page":"e226","DOI":"10.1016\/j.jaad.2012.04.029","article-title":"Prolonged response using gefitinib followed by sirolimus for advanced cutaneous squamous cell carcinoma","volume":"67","author":"Bossi","year":"2012","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.ejca.2018.04.004_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"issue":"2","key":"10.1016\/j.ejca.2018.04.004_bib13","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/cncr.29738","article-title":"Evaluation of 122 advanced-stage cutaneous squamous cell carcinomas by comprehensive genomic profiling opens the door for new routes to targeted therapies","volume":"122","author":"Al-Rohil","year":"2016","journal-title":"Cancer"},{"issue":"24","key":"10.1016\/j.ejca.2018.04.004_bib14","doi-asserted-by":"crossref","first-page":"6582","DOI":"10.1158\/1078-0432.CCR-14-1768","article-title":"Mutational landscape of aggressive cutaneous squamous cell carcinoma","volume":"20","author":"Pickering","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.ejca.2018.04.004_bib15","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1002\/cam4.669","article-title":"AKT1 and BRAF mutations in pediatric aggressive fibromatosis","volume":"5","author":"Meazza","year":"2016","journal-title":"Cancer Med"},{"issue":"10","key":"10.1016\/j.ejca.2018.04.004_bib16","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1093\/annonc\/mdu368","article-title":"Phase II study of single-agent panitumumab in patients with incurable cutaneous squamous cell carcinoma","volume":"25","author":"Foote","year":"2014","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2018.04.004_bib17","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/annonc\/mds503","article-title":"A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and\/or metastatic squamous-cell carcinoma of the head and neck","volume":"24","author":"Abdul Razak","year":"2013","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2018.04.004_bib18","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/S1470-2045(14)70452-8","article-title":"Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial","volume":"15","author":"Ramalingam","year":"2014","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2018.04.004_bib19","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1007\/s10120-015-0567-z","article-title":"Phase II trial of dacomitinib in patients with HER2-positive gastric cancer","volume":"19","author":"Oh","year":"2016","journal-title":"Gastric Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2018.04.004_bib20","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ctrv.2013.08.005","article-title":"Papillomavirus-associated squamous skin cancers following transplant immunosuppression: one Notch closer to control","volume":"40","author":"Connolly","year":"2014","journal-title":"Cancer Treat Rev"},{"issue":"27","key":"10.1016\/j.ejca.2018.04.004_bib21","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1200\/JCO.2011.40.9433","article-title":"Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer","volume":"30","author":"Ramalingam","year":"2012","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2018.04.004_bib22","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1093\/annonc\/mdv593","article-title":"Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials","volume":"27","author":"Ramalingam","year":"2016","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2018.04.004_bib23","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1093\/annonc\/mdv186","article-title":"Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors","volume":"26","author":"Kris","year":"2015","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2018.04.004_bib24","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1158\/1078-0432.CCR-14-1756","article-title":"Phase II clinical and exploratory biomarker study of dacomitinib in patients with recurrent and\/or metastatic squamous cell carcinoma of head and neck","volume":"21","author":"Kim","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.ejca.2018.04.004_bib25","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.ccr.2005.11.006","article-title":"A knotty turnabout?: Akt1 as a metastasis suppressor","volume":"8","author":"Wyszomierski","year":"2005","journal-title":"Cancer Cell"},{"issue":"46","key":"10.1016\/j.ejca.2018.04.004_bib26","doi-asserted-by":"crossref","first-page":"74820","DOI":"10.18632\/oncotarget.11204","article-title":"Akt isoform specific effects in ovarian cancer progression","volume":"7","author":"Linnerth-Petrik","year":"2016","journal-title":"Oncotarget"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980491830786X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980491830786X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,21]],"date-time":"2018-08-21T19:54:40Z","timestamp":1534881280000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095980491830786X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":26,"alternative-id":["S095980491830786X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2018.04.004","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of single-agent pan-human epidermal growth factor receptor (HER) inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2018.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}